Journey Medical Corporation’s Emrosi (40mg Minocycline Hydrochloride Modified-Release Capsules, 10mg immediate release and 30mg extended release) is now available for the treatment of inflammatory lesions of rosacea in adults by prescription at specialty pharmacy chains.
The U.S. Food and Drug Administration approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024.
“We are thrilled that the initial distribution to pharmacies is ongoing and the first Emrosi prescriptions have been filled,” says Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, in a news release. “Rosacea is a challenging condition that affects millions, and Emrosi, the lowest-dose oral minocycline on the market, delivers significantly superior clinical outcomes for rosacea compared to Oracea and placebo, while maintaining a comparable safety profile, as demonstrated in clinical trials. The launch of Emrosi marks a major milestone for Journey Medical and underscores our commitment to improving the quality of life for those living with dermatology conditions such as rosacea.”
For full prescribing information, please visit www.emrosi.com.
